CONTENTS:
- Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Smart R., Pardo B., Davis C.S., p. 6-17.
- Prevalence of alcohol use disorder among individuals who binge eat: a systematic review and meta-analysis. Bogusz K., Kopera M., Jakubczyk A., Trucco E.M., Kucharska K., Walenda A., et al., p. 18-31.
- Setting Limits: Gambling, Science and Public Policy - summary of results [Book Summary]. Sulkunen P., Babor T.F., Cisneros Örnberg J., Egerer M., Hellman M., Livingstone C., et al., p. 32-40.
- Impact of health warning labels communicating the risk of cancer on alcohol selection: an online experimental study. Clarke N., Pechey E., Mantzari E., Blackwell A.K.M., De-Loyde K., Morris R.W., et al., p. 41-52.
- Socio-economic differences in all-cause mortality in people with alcohol use disorder: a prospective cohort study. Rossow I., Amundsen E.J., Samuelsen S.O., p. 53-59.
- Commentary on Rossow et al.: The directions and tools to pursue a public health-orientated alcohol policy. Ghosh A., Mahintamani T., Choudhury S., p. 60-61.
- Similar countries, similar factors? Studying the decline of heavy episodic drinking in adolescents in Finland, Norway and Sweden. Raitasalo K., Kraus L., Bye E.K., Karlsson P., Tigerstedt C., Törrönen J., et al., p. 62-71.
- Commentary on Raitasalo et al.: Looking beyond the borders-what else is driving the decline in adolescent alcohol consumption? Vashishtha R., Livingston M., p. 72-73.
- Unemployment from stable, downsized and closed workplaces and alcohol-related mortality. Junna L., Moustgaard H., Martikainen P., p. 74-82.
- The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Farnum S.O., Makarenko I., Madden L., Mazhnaya A., Marcus R., Prokhorova T., et al., p. 83-93.
- Commentary on Farnum et al.: Agonist maintenance in Ukraine-ambivalence, success and moving forward. Woody G.E., p. 94-95.
- Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Lin L.A., Bohnert A.S.B., Blow F.C., Gordon A.J., Ignacio R.V., Kim H.M., et al., p. 96-104.
- Commentary on Lin et al.: Saving lives during the opioid crisis-widening the focus from opioid use disorder to polysubstance use disorder and to multimorbidity. Manhapra A., Rosenheck R., p. 105-106.
- 'It's just basically a box full of disease' - navigating sterile syringe scarcity in a rural New England state. Pollini R.A., Paquette C.E., Slocum S., LeMire D., p. 107-115.
- On the stability and the progression of gambling problems: longitudinal relations between different problems related to gambling. Sleczka P., Romild U., p. 116-125.
- Avoidance of tobacco health warnings? An eye-tracking approach. Sillero-Rejon C., Leonards U., Munafo M.R., Hedge C., Hoek J., Toll B., et al., p. 126-138.
- Changes from 2017 to 2018 in e-cigarette use and in ever marijuana use with e-cigarettes among US adolescents: analysis of the National Youth Tobacco Survey. Farsalinos K., Barbouni A., Niaura R., p. 139-149.
- The effect of tobacco and alcohol consumption on poverty in the United Kingdom. Nyakutsikwa B., Britton J., Langley T., p. 150-158.
- Effect of screening, brief intervention and referral to treatment for unhealthy alcohol and other drug use in mental health treatment settings: a randomized controlled trial. Karno M.P., Rawson R., Rogers B., Spear S., Grella C., Mooney L.J., et al., p. 159-169.
- Determinants of prescription opioid use: population-based evidence from Finland. Böckerman P., Haapanen M., Hakulinen C., Karhunen H., Maczulskij T., p. 170-175.
- Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross-sectional study. Schimmel J., Amioka E., Rockhill K., Haynes C.M., Black J.C., Dart R.C., et al., p. 176-181.
- Cannabis use disorder and the lungs. Gracie K., Hancox R.J., p. 182-190.
- Comparison of a web-push survey research protocol with a mailed paper and pencil protocol in the Monitoring the Future panel survey. Patrick M.E., Couper M.P., Parks M.J., Laetz V., Schulenberg J.E., p. 191-199.
- Commentary on Patrick et al.: Similar methodological studies are essential for general population surveys. Greenfield T.K., Martinez P., p. 200-201.
- Kratom use in the United States: a diverse and complex profile. Grundmann O., Babin J.K., Henningfield J.E., Garcia-Romeu A., Kruegel A.C., Prozialeck W.C., et al., p. 202-203.
- Kratom use in the United States: Response to Grundmann et al. Schimmel J., Amioka E., Rockhill K., Haynes C.M., Black J.C., Dart R.C., et al., p. 203-204.
- Alcohol: a probable risk factor of COVID-19 severity. Saengow U., Assanangkornchai S., Casswell S., p. 204-205.
- CRAFT: Treatment integrity is imperative for understanding research findings. Roozen H.G., Tsuji Y., Meyers R.J., p. 205-206.
- Response to Marsden et al (2020): Mitigation for the impacts on needle and syringe programmes is needed. Whitfield M., Reed H., Webster J., Hope V., p. 206-207.
- Challenging CBD protective effect against THC-related outcomes: a call for robust clinical trials. Mongeau-Pérusse V., Jutras-Aswad D., p. 207-208.